None
Quote | SCYNEXIS Inc. (NASDAQ:SCYX)
Last: | $1.4998 |
---|---|
Change Percent: | 5.25% |
Open: | $1.42 |
Close: | $1.425 |
High: | $1.52 |
Low: | $1.42 |
Volume: | 122,107 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | SCYNEXIS Inc. (NASDAQ:SCYX)
JERSEY CITY, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will pre...
In vivo data demonstrated response rate for oral SCY-247 similar to current standard of care, intravenous Liposomal Amphotericin B, for the treatment of mucormycosis Combination of SCY-247 and Liposomal Amphotericin B showed significant enhancement in survival and reduction in fungal burd...
Message Board Posts | SCYNEXIS Inc. (NASDAQ:SCYX)
Subject | By | Source | When |
---|---|---|---|
Gap fills in the 1.8's, golden cross around | BooDog | investorshub | 04/24/2023 3:12:38 PM |
Buy orders getting triggered. Just watch | BooDog | investorshub | 04/12/2023 4:40:04 PM |
Placed a buy order at 3.39 and took | duderaja | investorshub | 04/04/2023 2:08:55 PM |
Check this out: | duderaja | investorshub | 04/03/2023 7:28:52 PM |
$SCYX: Hey, THANKS, Capt. S-L!!! (& best of | Invest-in-America | investorshub | 04/03/2023 6:41:25 PM |
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to ov...
JERSEY CITY, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will pre...
In vivo data demonstrated response rate for oral SCY-247 similar to current standard of care, intravenous Liposomal Amphotericin B, for the treatment of mucormycosis Combination of SCY-247 and Liposomal Amphotericin B showed significant enhancement in survival and reduction in fungal burd...